This is a marketing communication.

Driehaus US Small Cap Equity Fund

A USD Acc (IE00BH3Z9P87)

Portfolio Management

Jeff James

Michael Buck

Prakash Vijayan

Key Facts

Sub-Investment Manager	DRIEHAUS CAPITAL MANAGEMENT
Investment Team Location	Chicago, Illinois, USA
Active/Passive	Active with reference to a benchmark
SFDR Classification	Article 8
Primary Benchmark	Russell 2000 Growth TR USD
Fund Size	$1,106m
Total No. of Holdings	116
Fund Launch	31/07/2019
Fund Base Ccy	USD
Fund Status	Open to existing investors
Share Class Launch	14/11/2019
Share Class Ccy	US Dollar
Share Class Status	Open to existing investors
Strategy Launch	01/01/1980
Strategy Size	$6.5bn
Management Fee	1.50%
Min. Investment	$15,000
Fund Type	UCITS
Domicile	Ireland
Management Company	Carne Management Company Ireland
Administrator	BBH Fund Administration Services (Ireland) Ltd
Depositary	BBH Trustee Services (Ireland) Ltd
Auditor	Grant Thornton
Dealing	Daily by 2pm Irish Time
Subscriptions	T+2
Redemptions	T+3

Investment Objective and Strategy

The investment objective of the Fund is to achieve long-term capital growth.

The Fund's Sub-Investment Manager, Driehaus Capital Management LLC, is a privately-held boutique asset management firm located in Chicago, USA. The firm was founded in 1982 and has USD 29.1 billion of assets under management.

The strategy primarily invests in US small-capitalisation companies with good growth potential and with a market capitalisation within the same range at the time of investment as those included in the Russell 2000® Growth Index. Investment decisions are based on the belief that fundamentally strong companies are more likely to generate superior earnings growth on a sustained basis and are more likely to experience positive earnings revisions. Investment decisions involve evaluating a company's competitive position, industry dynamics, identifying potential growth catalysts and assessing the financial position of the relevant company.

Performance

	1 month	3 months	YTD	1 Yr	3 Yrs Ann.	5 Yrs Ann.
Fund	-2.9%	-7.9%	4.1%	3.0%	20.9%	1.8%
Primary Benchmark	-1.3%	-5.0%	9.3%	7.1%	20.2%	3.5%
+/-	-1.6%	-2.9%	-5.2%	-4.2%	+0.6%	-1.7%



Statistics

	Fund	Primary Benchmark
Sharpe Ratio	-0.09	-0.02
Standard Deviation	23.2%	22.0%
Alpha	-1.3%	-
Up Capture	93.5%	100.0%
Down Capture	98.8%	100.0%

	Fund
Tracking Error	8.1%
Excess Return	-1.7%
Beta	0.99
Correlation to Primary Benchmark	0.94
Information Ratio	-0.21

Source: FactSet, as of 31.10.2026
Period 5 Years, Net of fees

Past performance does not predict future returns, the value of investments and income from them can fall as well as rise.

This is a marketing communication.

Driehaus US Small Cap Equity Fund

A USD Acc (IE00BH3Z9P87)

Top 10 Holdings

Guardant Health, Inc.	2.8%
Spyre Therapeutics, Inc.	2.0%
Twist Bioscience Corporation	1.9%
Praxis Precision Medicines, Inc.	1.8%
Definium Therapeutics Inc.	1.7%
Zeta Global Holdings Corp.	1.6%
Fastly, Inc.	1.6%
Xometry, Inc.	1.6%
Edgewise Therapeutics, Inc.	1.6%
JFrog Ltd.	1.4%
Total of Top 10	**18.0%**

Source: FactSet, as of 30.09.2026

Sector Weights



Historical Monthly Returns - Net of fees

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year	Primary Benchmark Year
2019											3.0%	3.2%	6.3%	6.1%
2020	-0.1%	-5.3%	-20.9%	17.0%	15.5%	6.1%	6.0%	6.7%	0.5%	1.6%	16.5%	10.1%	59.1%	34.6%
2021	6.3%	6.2%	-3.8%	3.2%	-2.6%	4.5%	-1.8%	3.4%	-1.2%	8.6%	-2.9%	-0.4%	19.9%	2.8%
2022	-19.8%	1.1%	-1.3%	-12.1%	-2.8%	-8.2%	9.6%	1.3%	-7.6%	9.1%	-0.1%	-7.9%	-35.4%	-26.4%
2023	6.0%	0.2%	-2.0%	-0.3%	0.9%	8.3%	3.8%	-1.7%	-6.5%	-8.5%	8.3%	9.8%	17.8%	18.7%
2024	3.7%	11.6%	2.8%	-6.6%	5.9%	1.0%	0.5%	1.5%	3.4%	-1.0%	11.7%	-9.6%	25.3%	15.2%
2025	1.4%	-9.4%	-10.0%	1.6%	4.6%	6.1%	3.1%	5.1%	6.6%	6.8%	0.6%	-1.6%	13.9%	13.0%
2026	6.0%	1.5%	-6.9%	13.6%	5.3%	5.1%	-10.2%	0.5%	-5.7%	-2.9%			4.1%	9.3%

Source: FactSet, as of 31.10.2026

Past performance does not predict future returns, the value of investments and income from them can fall as well as rise.

This is a marketing communication.

Driehaus US Small Cap Equity Fund

A USD Acc (IE00BH3Z9P87)

Available Share Classes

Name	Ccy	Dist/Acc	Hedged	ISIN	Bloomberg	SEDOL
A	USD	Acc	-	IE00BH3Z9P87	HEPSMCA ID	BH3Z9P8
A1	USD	Acc	-	IE00BH3Z9Q94	HPSMCA1 ID	BH3Z9Q9
ACH	CHF	Acc	-	IE00BH3Z9R02	HPSMACH ID	BH3Z9R0
ACH1	CHF	Acc	-	IE00BH3Z9S19	HSMACH1 ID	BH3Z9S1
ACHH	CHF	Acc	Yes	IE00BH3Z9T26	HSMACHH ID	BH3Z9T2
ACHH1	CHF	Acc	Yes	IE00BH3Z9V48	HSACHF1 ID	BH3Z9V4
AD	USD	Dist	-	IE00BH3Z9W54	HPSMCAD ID	BH3Z9W5
AD1	USD	Dist	-	IE00BH3Z9X61	HPSMAD1 ID	BH3Z9X6
AE	EUR	Acc	-	IE00BH3Z9Y78	HPSMCAE ID	BH3Z9Y7
AE1	EUR	Acc	-	IE00BH3Z9Z85	HPSMAE1 ID	BH3Z9Z8
AED	EUR	Dist	-	IE00BH3ZB074	HPSMAED ID	BH3ZB07
AED1	EUR	Dist	-	IE00BH3ZB181	HSMAED1 ID	BH3ZB18
AEH	EUR	Acc	Yes	IE00BH3ZB298	HPSMAEH ID	BH3ZB29
AEH1	EUR	Acc	Yes	IE00BH3ZB306	HSMAEH1 ID	BH3ZB30
AF	USD	Acc	-	IE00BDB0W360	HPSMCAF ID	BDB0W36
AG	GBP	Acc	-	IE00BH3ZB413	HPSMCAG ID	BH3ZB41
AG1	GBP	Acc	-	IE00BH3ZB520	HPSMAG1 ID	BH3ZB52
AGD	GBP	Dist	-	IE00BH3ZB637	HPSMAGD ID	BH3ZB63
AGD1	GBP	Dist	-	IE00BH3ZB744	HSMAGD1 ID	BH3ZB74
AR	CNY	Acc	-	IE00BDB0VY03	HPSMCAR ID	BDB0VY0

Risk Warnings

The Fund is subject to special risk considerations including geographic concentration risk, portfolio concentration risk and operational risk. The investment return and principal value of an investment will fluctuate so that the investor's shares, when redeemed, may be worth more or less than their original cost. Any investor should consider the investment objectives, risks and charges and expenses of the Fund carefully before investing. Where an investment is denominated in a currency other than the investor's currency, changes in rates of exchange may have an adverse effect on the value, price of, or income derived from the investment.

Important Information and Disclosure

Heptagon Capital Limited, Heptagon Capital LLP and its affiliate companies and its members, officers, employees, agents and advisors disclaim any and all liability relating to these materials, except to the extent required by applicable law or regulations, including, without limitation, any express or implied representations or warranties for statements or errors contained in, and omissions from, these materials. Certain assumptions have been made, and/or parameters set, in the preparation of these materials which have resulted in the returns detailed herein, and no representation or warranty is made that any returns indicated will be achieved. Changes to assumptions or parameters may have a material impact on the returns detailed. This document should not be copied to any other person without our express consent. This document should not be considered an offer to buy or sell investments.

Heptagon Capital Limited has issued this communication as investment manager for Heptagon Fund ICAV (the "Company"), an umbrella fund with segregated liability between sub-funds (the "Funds") and authorised pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011, as amended, and is licensed to conduct investment services by the Malta Financial Services Authority.

Heptagon Capital LLP is authorised and regulated in the UK by the Financial Conduct Authority (FRN: 403304) and is the sub-investment manager for a number of the Funds.

Representative and Paying Agent in Switzerland is Société Générale, Paris, Zurich branch, Talacker 50, PO Box 1928, 8021 Zurich, Switzerland. The prospectus, the key investor information document, the Articles and the annual and semi-annual reports are available free of charge from the Swiss representative.

The results given in this document are based solely upon historical fund performance as gathered and supplied by FactSet. That past performance has not been independently verified by either Heptagon Capital Limited or Heptagon Capital LLP. It is not intended to predict or depict the future performance of any investment.

The information contained herein is provided for informational purposes only, is not complete, and does not contain certain material information about the Funds, including important disclosures and risk factors associated with an investment in the Funds. Before making an investment in any Fund, prospective investors are advised to thoroughly and carefully review the Company's prospectus (the "Prospectus") as well as the supplement to the Prospectus for the Fund and the Fund's Key Information Document (KID) with their financial, legal and tax advisors to determine whether an investment is suitable for them. The investment being promoted concerns the acquisition of shares in the Fund; investors will not own the Fund's underlying assets.

For all definitions of the financial terms used within this document, please refer to the glossary on our website: https://www.heptagon-capital.com/glossary.

Past performance does not predict future returns, the value of investments and income from them can fall as well as rise.

This is a marketing communication.

Driehaus US Small Cap Equity Fund

A USD Acc (IE00BH3Z9P87)

Important Information and Disclosure

London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. Russell® is a trade-mark of the relevant LSE Group companies and is used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and S&P Global Market Intelligence ("S&P") and is licensed for use by Heptagon Fund ICAV. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.